Septerna (NASDAQ:SEPN) Stock Price Target Raised at Stifel Nicolaus

Septerna (NASDAQ:SEPN) had its price target upped by stock analysts at Stifel Nicolaus from $49.00 to $60.00 in a report released on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus‘s target price suggests a potential upside of 18.24% from the company’s previous close.

A number of other research firms have also recently issued reports on SEPN. JonesTrading increased their target price on Septerna from $43.00 to $62.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Raymond James Financial reissued a “strong-buy” rating and issued a $49.00 target price on shares of Septerna in a research report on Tuesday, August 11th. HC Wainwright lifted their price objective on shares of Septerna from $40.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research report on Thursday, October 15th. Finally, Guggenheim increased their price objective on shares of Septerna from $51.00 to $65.00 and gave the stock a “buy” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Septerna has a consensus rating of “Moderate Buy” and a consensus target price of $56.44.

Septerna Trading Up 0.0%

SEPN stock traded up $0.01 during trading on Tuesday, hitting $50.74. The company had a trading volume of 39,046 shares, compared to its average volume of 363,903. The company has a fifty day moving average price of $39.76 and a two-hundred day moving average price of $32.71. The company has a market cap of $2.37 billion, a P/E ratio of -93.08 and a beta of 2.20. Septerna has a fifty-two week low of $18.19 and a fifty-two week high of $51.10.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.15). The business had revenue of $18.88 million during the quarter, compared to analyst estimates of $20.78 million. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%. On average, analysts expect that Septerna will post -1.41 earnings per share for the current year.

Insider Activity

In other news, SVP Daniel Long sold 3,333 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $37.83, for a total value of $126,087.39. Following the completion of the transaction, the senior vice president directly owned 96,412 shares in the company, valued at approximately $3,647,265.96. This trade represents a 3.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Elizabeth Bhatt sold 4,000 shares of Septerna stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $37.41, for a total transaction of $149,640.00. Following the completion of the transaction, the chief operating officer owned 174,209 shares in the company, valued at approximately $6,517,158.69. The trade was a 2.24% decrease in their position. The SEC filing for this sale provides additional information. 5.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Septerna

Several hedge funds and other institutional investors have recently modified their holdings of the stock. TRV GP V LLC purchased a new stake in shares of Septerna during the second quarter worth about $208,160,143. TRV GP VI LLC bought a new stake in shares of Septerna during the second quarter valued at approximately $141,048,460. BlackRock Inc. purchased a new position in Septerna during the second quarter valued at $64,706,000. Jupiter Topco LLC purchased a new stake in Septerna in the 2nd quarter worth $43,723,000. Finally, Primecap Management Co. CA purchased a new stake in Septerna in the 2nd quarter worth $39,096,000.

About Septerna

Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California.

Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.

Founded in 2021, Septerna has no marketed products; its work is focused on research and clinical development.